Somatuline Autogel (lanreotide): Reviews and patient testimonials

/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1720004028

Medication indications

Somatuline Autogel 60mg, Somatuline Autogel 90mg, Somatuline Autogel 120mg

Somatuline Autogel is indicated for:

• The treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels and where possible to normalise these values.

• The treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.

• The treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumours.


Molecule: lanreotide

Patients' opinions on Somatuline Autogel

In brief

General satisfaction level: 7.67/10 Learn more

Treatment's effectiveness: 9.67/10 Learn more

Ease of use: 5.67/10 Learn more

Adherence to prescription: 8.67/10 Learn more

Detected side effects: 5.67/10 Learn more

Improvement in the quality of life: 8.00/10 Learn more

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.

Conditions related to this medication

See the fact sheet
Fact sheet

Acromegaly

See the fact sheet